Action LEGN LEGEND BIOTECH CORPORATION
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Legend Biotech Corporation

Actions

LEGN

US52490G1022

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
45,3 USD +1,98% Graphique intraday de Legend Biotech Corporation -1,93% -24,71%
22/04 CARVYKTI® (ciltacabtagene autoleucel) de Legend Biotech Corporation approuvé par la Commission européenne pour le traitement de deuxième intention des patients atteints de myélome multiple récidivant et réfractaire CI
17/04 LEGEND BIOTECH CORPORATION : Scotiabank passe à l'achat ZM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission
Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Legend Biotech Corporation's CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
US FDA mandates label updates on CAR-T cancer therapies
Genscript Biotech's Unit Logs $157 Million in Q1 Sales of Blood Cancer Drug
Legend Biotech : Announces Preliminary Sales for CARVYKTI® for the Quarter Ended March 31, 2024 - Form 6-K
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Genscript Biotech Unit's Refractory Multiple Myeloma Drug Gets FDA Approval
Innovative personalised immunotherapy approved for multiple myeloma
Sector Update: Health Care Stocks Flat to Higher Premarket Monday
Johnson & Johnson, Legend Biotech's Carvykti Receives FDA Approval to Treat Relapsed, Refractory Multiple Myeloma
U.S. FDA approves expanded use of J&J's cancer cell therapy
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Legend Biotech Corporation's CARVYKTI Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer
U.S. FDA allows expanded use of Bristol Myers' cell therapy
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance Report
Legend Biotech Files Mixed-Securities Shelf Registration
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action LEGN
  4. Actualités Legend Biotech Corporation
  5. Autres langues